Fries Dietmar, Innerhofer Petra, Klingler Anton, Berresheim Ulrike, Mittermayr Markus, Calatzis Andreas, Schobersberger Wolfgang
Department of Anesthesia and Intensive Care Medicine, The Leopold-Franzens-University of Innsbruck, Austria.
Anesth Analg. 2002 May;94(5):1280-7, table of contents. doi: 10.1097/00000539-200205000-00043.
Gelatin solutions are often given in clinical practice once the maximal dose of a median-weight hydroxyethyl starch (HES) has been reached. Colloids are usually combined with lactated Ringer's solution (RL). Whether the combined administration of colloids and/or crystalloids affects blood coagulation is not known. We diluted blood by 20%, 40%, and 60% with RL, gelatin (Gelofusin), 6% HES 130/0.4 (Voluven), and 6% HES 200/0.5 (Iso-Hes), as well as with combinations of these solutions at a ratio of 1:1 (gelatin/RL, 6% HES 130/0.4:RL, 6% HES 200/0.5:RL, 6% HES 130/0.4:gelatin, 6% HES 200/0.5:gelatin). Thereafter, blood was analyzed by using modified thrombelastograph coagulation analysis (ROTEG) and clotting time, clot formation time, and maximal clot firmness were determined. RL had the least effect on hemostasis. Gelatin administered alone impaired the coagulation system significantly less than each median-weight HES administered alone. We conclude that gelatin combined with 6% HES 200/0.5 or 6% HES 130/0.4 decreases hemostasis <6% HES 200/0.5 or 6% HES 130/0.4 administered alone.
The effect of the combined administration of different colloids and/or crystalloids on coagulation is not known. We show that hemostasis is less impaired using a combination of gelatin and median-weight starches than using median-weight starches alone. Furthermore, the combination of lactated Ringer's solution and gelatin decreases the coagulation system to the same extent as the combination of lactated Ringer's solution and 6% hydroxyethyl starch 130/0.4.
在临床实践中,一旦达到中等分子量羟乙基淀粉(HES)的最大剂量,通常会给予明胶溶液。胶体通常与乳酸林格氏液(RL)联合使用。胶体和/或晶体液的联合给药是否会影响血液凝固尚不清楚。我们用RL、明胶(血定安)、6% HES 130/0.4(万汶)和6% HES 200/0.5(贺斯),以及这些溶液按1:1比例混合(明胶/RL、6% HES 130/0.4:RL、6% HES 200/0.5:RL、6% HES 130/0.4:明胶、6% HES 200/0.5:明胶)将血液稀释20%、40%和60%。此后,使用改良血栓弹力图凝血分析(ROTEG)对血液进行分析,并测定凝血时间、凝血形成时间和最大血凝块硬度。RL对止血的影响最小。单独给予明胶对凝血系统的损害明显小于单独给予的每种中等分子量HES。我们得出结论,明胶与6% HES 200/0.5或6% HES 130/0.4联合使用比单独给予6% HES 200/0.5或6% HES 130/0.4更能降低止血效果。
不同胶体和/或晶体液联合给药对凝血的影响尚不清楚。我们表明,与单独使用中等分子量淀粉相比,明胶与中等分子量淀粉联合使用对止血的损害更小。此外,乳酸林格氏液和明胶的联合使用对凝血系统的降低程度与乳酸林格氏液和6%羟乙基淀粉130/0.4的联合使用相同。